[{"orgOrder":0,"company":"Safety Shot","sponsor":"Applied Biology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Initiates Clinical Trial for Potential New Treatment for Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pimozide","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Safety Shot","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Safety Shot \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Safety Sho.."}]

Find Clinical Drug Pipeline Developments & Deals for NCGC00024888-07

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : This study aims to investigate if the dopamine receptor antagonist Pimozide can be used effectively treat COVID-19 for tinnitus, emergent symptoms lasting longer than 4 weeks since onset.

                          Brand Name : JW-600

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 06, 2022

                          Lead Product(s) : Pimozide

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : Applied Biology

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank